Form 4: DiaMedica Therapeutics Director Richard D. Pilnik Acquires Shares in Lieu of Cash Retainer Fees

Director Richard D. Pilnik acquired 10,393 shares of DiaMedica Therapeutics Inc. in lieu of cash retainer fees, increasing his total holdings to 288,995 shares.

Summary

• On January 2, 2025, Richard D. Pilnik, a director of DiaMedica Therapeutics Inc., acquired 10,393 voting common shares.
• The shares were acquired in lieu of $55,500 in cash retainer fees under the company's Amended and Restated 2019 Omnibus Incentive Plan.
• The price per share was $5.34.
• Following the transaction, Pilnik's total beneficial ownership increased to 288,995 shares.
• These include shares issuable upon settlement of deferred share units and deferred stock units granted under the company's incentive plans.
• The deferred stock units will vest in four nearly equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director taking equity instead of cash can be seen as a positive sign, but it's a relatively small transaction.

Positives

• A director taking equity in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Directors receiving equity in lieu of cash compensation is a common practice, particularly in smaller companies, to conserve cash and align director interests with shareholders.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment.

Key Dates